Innovative Cryoablation Technology from IceCure Shines at SIO Annual Meeting
IceCure Medical Ltd. recently gained significant attention during the Society of Interventional Oncology (SIO) Annual Meeting held from January 29 to February 3, 2025, in Las Vegas. This event highlighted the company’s innovative ProSense® cryoablation technology, which offers a minimally invasive alternative for treating breast cancer by freezing tumors instead of traditional surgical methods.
At the SIO meeting, two independent studies showcasing the safety and efficacy of ProSense® in breast cancer were presented. One notable research paper, conducted in the Netherlands, was honored with the "Highest Scoring Abstract" award in its category. This study, titled "The Treatment of Breast Cancer with Percutaneous Thermal Ablation - Results of the THERMAC Trial," concluded that cryoablation, among various thermal ablation techniques, met the necessary benchmarks required for a randomized Phase 3 trial evaluating thermal ablation against conventional surgery.
The details of the THERMAC trial revealed that cryoablation achieved complete tumor ablation in an impressive 94% of patients, compared to 72% for microwave ablation (MWA). The Radiofrequency Ablation (RFA) group faced premature termination after reaching a defined stopping rule, highlighting the superior safety profile of cryoablation with zero adverse events recorded in its patients, in sharp contrast to the 44% adverse events in the MWA arm.
Accompanying the presentations was a Breast Cryoablation Mini Masterclass sponsored by IceCure, which took place on February 1. This session drew considerable participation and provided attendees with a comprehensive understanding of ablative therapies, particularly in the realm of breast cancer. Experts in the field, including renowned figures like Dr. Robert Ward and Dr. Franco Orsi, engaged with attendees, sharing insights on patient selection and treatment methodologies, further enhancing the potential for cryoablation in clinical practice.
IceCure's CEO, Eyal Shamir, expressed optimism regarding the medical community's interest in the ProSense® system, especially in light of the anticipated U.S. FDA decision on market authorization for early-stage breast cancer. Shamir stated, "We’re thrilled to witness the high level of interest from physicians who may be poised to adopt ProSense® upon approval in the U.S. The presentations by doctors from the Netherlands and Romania received positive reactions and demonstrate a growing eagerness to incorporate cryoablation into patient care."
The second study, titled "Initial Experience in Romania - Tumor Reduction and Safety Outcomes of Percutaneous Cryoablation for Benign and Malignant Breast Lesions at a Single Center," provided an overview of the promising outcomes of using a liquid nitrogen-based cryoablation system. Conducted at the Saint Nectarie Oncology Center in Romania, this research underscored the effectiveness and safety of cryoablation for breast lesions ≤35 mm, reporting a technical success rate of 100%. The investigators, including Georgiana-Cristiana Camen and Michael Schenker, noted high levels of satisfaction among both physicians and patients, paving the way for the integration of cryoablation into routine breast cancer treatment protocols at their center.
The ProSense® Cryoablation System stands out due to its innovative use of liquid nitrogen, facilitating large lethal zones necessary for effectively targeting both benign and malignant tumors. This system is designed for rapid recovery, reduced pain, and fewer surgical risks compared to more invasive procedures, making it a compelling choice for office-based interventions.
In conclusion, IceCure Medical is at the forefront of advancing breast cancer treatment through cutting-edge technology like the ProSense® cryoablation system. With strong research backing and an enthusiastic reception within the medical community, the company is poised for significant recognition, especially as they await the FDA's decision in early 2025. The potential for cryoablation in transforming standard breast cancer care has never been more promising, making it a pivotal focus for both medical professionals and patients in the near future.
At the SIO meeting, two independent studies showcasing the safety and efficacy of ProSense® in breast cancer were presented. One notable research paper, conducted in the Netherlands, was honored with the "Highest Scoring Abstract" award in its category. This study, titled "The Treatment of Breast Cancer with Percutaneous Thermal Ablation - Results of the THERMAC Trial," concluded that cryoablation, among various thermal ablation techniques, met the necessary benchmarks required for a randomized Phase 3 trial evaluating thermal ablation against conventional surgery.
The details of the THERMAC trial revealed that cryoablation achieved complete tumor ablation in an impressive 94% of patients, compared to 72% for microwave ablation (MWA). The Radiofrequency Ablation (RFA) group faced premature termination after reaching a defined stopping rule, highlighting the superior safety profile of cryoablation with zero adverse events recorded in its patients, in sharp contrast to the 44% adverse events in the MWA arm.
Accompanying the presentations was a Breast Cryoablation Mini Masterclass sponsored by IceCure, which took place on February 1. This session drew considerable participation and provided attendees with a comprehensive understanding of ablative therapies, particularly in the realm of breast cancer. Experts in the field, including renowned figures like Dr. Robert Ward and Dr. Franco Orsi, engaged with attendees, sharing insights on patient selection and treatment methodologies, further enhancing the potential for cryoablation in clinical practice.
IceCure's CEO, Eyal Shamir, expressed optimism regarding the medical community's interest in the ProSense® system, especially in light of the anticipated U.S. FDA decision on market authorization for early-stage breast cancer. Shamir stated, "We’re thrilled to witness the high level of interest from physicians who may be poised to adopt ProSense® upon approval in the U.S. The presentations by doctors from the Netherlands and Romania received positive reactions and demonstrate a growing eagerness to incorporate cryoablation into patient care."
The second study, titled "Initial Experience in Romania - Tumor Reduction and Safety Outcomes of Percutaneous Cryoablation for Benign and Malignant Breast Lesions at a Single Center," provided an overview of the promising outcomes of using a liquid nitrogen-based cryoablation system. Conducted at the Saint Nectarie Oncology Center in Romania, this research underscored the effectiveness and safety of cryoablation for breast lesions ≤35 mm, reporting a technical success rate of 100%. The investigators, including Georgiana-Cristiana Camen and Michael Schenker, noted high levels of satisfaction among both physicians and patients, paving the way for the integration of cryoablation into routine breast cancer treatment protocols at their center.
The ProSense® Cryoablation System stands out due to its innovative use of liquid nitrogen, facilitating large lethal zones necessary for effectively targeting both benign and malignant tumors. This system is designed for rapid recovery, reduced pain, and fewer surgical risks compared to more invasive procedures, making it a compelling choice for office-based interventions.
In conclusion, IceCure Medical is at the forefront of advancing breast cancer treatment through cutting-edge technology like the ProSense® cryoablation system. With strong research backing and an enthusiastic reception within the medical community, the company is poised for significant recognition, especially as they await the FDA's decision in early 2025. The potential for cryoablation in transforming standard breast cancer care has never been more promising, making it a pivotal focus for both medical professionals and patients in the near future.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.